These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 25793625)
41. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909 [TBL] [Abstract][Full Text] [Related]
42. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime. Campo Esquisabel AB; Rodríguez MC; Campo-Sosa AO; Rodríguez C; Martínez-Martínez L Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797 [TBL] [Abstract][Full Text] [Related]
43. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16. Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202 [TBL] [Abstract][Full Text] [Related]
44. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group. Lewis MT; Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587 [TBL] [Abstract][Full Text] [Related]
45. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201 [TBL] [Abstract][Full Text] [Related]
46. The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination. Smith KP; Kirby JE Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784837 [TBL] [Abstract][Full Text] [Related]
47. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study]. Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074 [TBL] [Abstract][Full Text] [Related]
48. The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria. Laudy AE; Kulińska E; Tyski S Molecules; 2017 Jan; 22(1):. PubMed ID: 28085074 [TBL] [Abstract][Full Text] [Related]
50. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Queenan AM; Shang W; Bush K; Flamm RK Antimicrob Agents Chemother; 2010 Oct; 54(10):4092-7. PubMed ID: 20606064 [TBL] [Abstract][Full Text] [Related]
51. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]
52. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group. Jones RN; Salazar JC; Pfaller MA; Doern GV Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984 [TBL] [Abstract][Full Text] [Related]
53. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Jones ME Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372 [TBL] [Abstract][Full Text] [Related]
55. The Influence of Efflux Pump Inhibitors on the Activity of Non-Antibiotic NSAIDS against Gram-Negative Rods. Laudy AE; Mrowka A; Krajewska J; Tyski S PLoS One; 2016; 11(1):e0147131. PubMed ID: 26771525 [TBL] [Abstract][Full Text] [Related]
56. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Castanheira M; Sader HS; Farrell DJ; Mendes RE; Jones RN Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066 [TBL] [Abstract][Full Text] [Related]
57. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? Moland ES; Sanders CC; Thomson KS J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395 [TBL] [Abstract][Full Text] [Related]
58. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates. Humphries RM; Hindler JA; Wong-Beringer A; Miller SA Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338 [TBL] [Abstract][Full Text] [Related]
59. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000 [TBL] [Abstract][Full Text] [Related]
60. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Aubert D; Poirel L; Chevalier J; Leotard S; Pages JM; Nordmann P Antimicrob Agents Chemother; 2001 Jun; 45(6):1615-20. PubMed ID: 11353602 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]